C1q activators constitute a diverse array of chemical entities that are characterized by their ability to enhance the functional activity of the C1q protein, a key component of the classical complement pathway. C1q is primarily recognized for its role in the immune system where it binds to the Fc region of antibodies that are attached to pathogens, triggering a series of immune responses that include the opsonization of pathogens and the initiation of a complement cascade resulting in the formation of a membrane attack complex. Activators of C1q can operate through various mechanisms, with some directly binding to the C1q molecule itself, thereby stabilizing its conformation and enhancing its ability to initiate the complement cascade. Others may work by upregulating the cellular pathways that lead to the expression and stabilization of C1q or its receptor interactions, which are essential for its proper functioning in the immune response. These chemicals, while diverse in structure, share the common feature of promoting the activity of C1q without necessarily increasing its expression.
The biochemical activation mechanisms of C1q activators can be quite intricate. Some activators may influence the configuration of C1q, facilitating its interaction with the C1r2s2 complex, which is a crucial step in the activation of the classical pathway. Other compounds may interact with various regulators of complement activation, such as C1 inhibitor (C1-INH), to sustain a favorable balance that promotes C1q function. By influencing the proteases that cleave and activate downstream components of the complement system, such as C4 and C2, these activators indirectly bolster the function of C1q. Although they do not directly modify the protein structure of C1q, their actions on related molecules and signaling pathways result in a net increase in the functional potential of C1q, thus enhancing its role in the immune system's defense mechanisms. Collectively, these activators work in concert to ensure that C1q can effectively fulfill its role in the recognition and clearance of pathogens, as well as in the removal of apoptotic cells, thereby maintaining homeostasis within the immune system.
제품명 | CAS # | 카탈로그 번호 | 수량 | 가격 | 引用 | RATING |
---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
히스톤 탈아세틸화 효소 억제제는 C1q 발현의 후성유전학적 조절을 수정하여 잠재적으로 그 활성에 변화를 일으킬 수 있습니다. | ||||||
MCC950 sodium salt | 256373-96-3 | sc-505904 sc-505904A sc-505904B sc-505904C | 5 mg 10 mg 50 mg 100 mg | $112.00 $194.00 $871.00 $1538.00 | 3 | |
MCC950과 같은 화합물은 NLRP3 인플라마좀을 억제할 수 있으며, 이는 C1q를 포함한 보체 활성화에 하류 영향을 미칠 수 있습니다. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-kB를 억제하는 BAY 11-7082와 같은 화합물은 C1q를 포함한 보체 시스템 유전자의 전사에 영향을 미칠 수 있습니다. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
PPARγ 작용제는 대식세포 기능을 조절하여 C1q 활성에 간접적으로 영향을 줄 수 있습니다. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $32.00 $75.00 $118.00 | 14 | |
스핑고신-1-인산 수용체 조절제는 림프구 배출과 기능에 영향을 미칠 수 있으며, C1q 활성에 잠재적인 하류 효과를 줄 수 있습니다. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 및 기타 TGF-β 경로 억제제는 C1q를 포함한 보체 성분의 발현에 영향을 미칠 수 있습니다. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $306.00 | 1 | |
IKK를 억제하는 화합물은 NF-kB 신호에 영향을 미쳐 C1q 발현에 영향을 줄 수 있습니다. |